Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE)

Ultragenyx Pharmaceutical (NASDAQ:RARE) is 1 of the 17 biotechnology stocks with much than 50% upside.

On February 3, the terms people connected Ultragenyx Pharmaceutical (NASDAQ:RARE) was acceptable to $60 by H.C. Wainwright expert Ram Selvaraju, who maintained a Buy standing connected the stock. The analyst’s estimation leads to a promising upside imaginable of much than 155% from the prevailing level.

Pressmaster/Shutterstock.com

Selvaraju attributed his views to the company’s awesome uncommon illness pipeline and expected regulatory milestones. He besides highlighted on-schedule BLA resubmission for UX111, which includes extended objective information showing sustained neurologic benefits and biomarker improvements. The filing besides includes an capable information illustration for Sanfilippo syndrome benignant A, which does not person immoderate approved therapies. The expert is optimistic astir the institution achieving profitability arsenic aboriginal arsenic 2027, which reflects favorably connected its charismatic risk-reward profile.

On January 28, Ultragenyx Pharmaceutical (NASDAQ:RARE) was assigned an Overweight standing by Barclays expert Eliana Merle. She estimated a people terms of $44, which yields much than 87% upside potential. Merle anticipates a much favorable outlook for biotech stocks, supported by robust fundamentals and forecasted continued mergers and acquisitions activity.

Ultragenyx Pharmaceutical (NASDAQ:RARE) develops caller therapies, with a absorption connected identifying, acquiring, and commercializing products for uncommon and ultra-rare familial diseases. It places beardown accent connected cistron therapy and covers the assorted stages of objective trials. The institution is presently experiencing precocious currency burn, with the purpose of becoming profitable from 2027 onward.

While we admit the imaginable of RARE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.